These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 38110710)

  • 1. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
    Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated CT Radiomics Features Could Enhance the Efficacy of
    Zhou W; Huang Q; Wen J; Li M; Zhu Y; Liu Y; Dai Y; Guan Y; Zhou Z; Hua T
    Front Oncol; 2021; 11():772703. PubMed ID: 34869011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive prediction of IDH mutation status in gliomas using preoperative multiparametric MRI radiomics nomogram: A mutlicenter study.
    Lu J; Xu W; Chen X; Wang T; Li H
    Magn Reson Imaging; 2023 Dec; 104():72-79. PubMed ID: 37778708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
    Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
    Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [
    Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
    Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
    BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
    Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
    J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-Stage Training Framework Using Multicontrast MRI Radiomics for
    Truong NCD; Bangalore Yogananda CG; Wagner BC; Holcomb JM; Reddy D; Saadat N; Hatanpaa KJ; Patel TR; Fei B; Lee MD; Jain R; Bruce RJ; Pinho MC; Madhuranthakam AJ; Maldjian JA
    Radiol Artif Intell; 2024 Jul; 6(4):e230218. PubMed ID: 38775670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
    Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
    J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
    Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Nomogram Modeling
    Zhou W; Zhou Z; Wen J; Xie F; Zhu Y; Zhang Z; Xiao J; Chen Y; Li M; Guan Y; Hua T
    Front Oncol; 2020; 10():1200. PubMed ID: 32850348
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [
    Kaiser L; Quach S; Zounek AJ; Wiestler B; Zatcepin A; Holzgreve A; Bollenbacher A; Bartos LM; Ruf VC; Böning G; Thon N; Herms J; Riemenschneider MJ; Stöcklein S; Brendel M; Rupprecht R; Tonn JC; Bartenstein P; von Baumgarten L; Ziegler S; Albert NL
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2371-2381. PubMed ID: 38396261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
    Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
    Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter clinical radiomics-integrated model based on [
    Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
    Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas.
    Wu S; Zhang X; Rui W; Sheng Y; Yu Y; Zhang Y; Yao Z; Qiu T; Ren Y
    Eur Radiol; 2022 May; 32(5):3187-3198. PubMed ID: 35133485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.
    Kebir S; Weber M; Lazaridis L; Deuschl C; Schmidt T; Mönninghoff C; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Sure U; Stuschke M; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Rischpler C; Glas M
    Clin Nucl Med; 2019 Mar; 44(3):214-220. PubMed ID: 30516675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.